Zacks.com on MSN4hOpinion
2 Great Stocks to Buy Now for at Least 30% Upside: AMD, DECK
The somewhat hot inflation data on Wednesday didn’t move the market. Wall Street was content to hold its ground and chop ...
CROX SHAREHOLDER ALERT: Crocs, Inc. Investors are Notified of Pending Class Action and are Urged to Contact BFA Law
New York, New York-- (Newsfile Corp. - February 13, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Crocs, Inc. (NASDAQ: CROX) and ...
STAT1d
Pharmalittle: We’re reading about pharma silence on Trump moves, lawmakers eyeing PBMs again, and more
A U.S. judge ordered federal agencies to restore access to health-related webpages and datasets removed by the Trump ...
Axsome Settling Teva Patent Litigation Is Another Positive Catalyst -- Upgrade
Axsome Therapeutics, Inc.'s' stock surges 30% amid key catalysts. Learn why it's now rated a Buy wih upcoming data opportunities. Click for my AXSM update.
Why Axsome Therapeutics (AXSM) Is Advancing Today
Axsome Therapeutics (AXSM) is climbing nearly 4% after Swiss bank UBS increased its price target on the shares to $133 from ...
Zacks.com on MSN2d
Axsome Stock Surges 20% on Auvelity Patent Settlement With Teva
Shares of Axsome Therapeutics AXSM jumped 20.2% on Monday after the company announced that it has entered into a settlement ...
Why Axsome Therapeutics Stock Is Skyrocketing Today
Shares of Axsome Therapeutics ( AXSM 20.22%) are flying higher on Monday. The company's stock is up 24.7% as of 1:10 p.m. ET, ...
Spotlight on Teva Pharmaceutical Indus: Analyzing the Surge in Options Activity
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...
BioPharma Dive3d
Axsome secures top drug’s future with Teva patent settlement
Shares in the brain drug developer rose by more than 20% Monday on news of the deal, which will forestall Teva's generic copy ...
Shares in Biopharma Firm Axsome Surge Over 20% After Settling Teva Patent Dispute
Shares in biopharmaceutical group Axsome Therapeutics (AXSM) surged 23% today after it said it had settled a legal dispute ...
Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025'
Axsome settles Auvelity patent litigation with Teva, delaying a generic launch until 2038. Analysts see growth potential with Symbravo's migraine approval.
FiercePharma3d
Axsome shares jump as settlement will keep Teva's Auvelity generic off the market until 2038
With the settlement, Teva will not market the Auvelity generic until September 30, 2038, Axsome said in a Monday press ...